Eficacia de la Vareniclina y Bupropión a los 3,6 y 9 meses para el tratamiento de la cesación de tabaco en Atención a Pacientes del IAFA en el año 2020

Abstract

Tobacco consumption and its complications clearly constitute one of the main preventable public health problems. In tobacco dependence, although it is a multicausal phenomenon, the neurochemical mechanisms of nicotine dependence prevail. Direct pharmacological intervention in the neurobiological systems that mediate nicotine dependence, associated with therapeutic support, has given excellent results in cessation programs. The four available alternatives, replacement therapy, cytisine, bupropion and varinicline have shown good efficacy. Bupropion has been used in cessation programs at the IAFA for 30 years with good results. This study shows the good tolerance and effectiveness of bupropion and varenicline, which is why their use is recommended in cessation programs in the country.